Ibandronate

Reference work entry
DOI: https://doi.org/10.1007/3-540-29662-X_1315

Trade Names

Boniva; Bondronate.

Class and Category

Anti-osteoporotic. Bisphosphonate drug class.

Indications

Prevention and treatment of osteoporosis in postmenopausal women, demonstrated to reduce the incidence of new vertebral insufficiency fractures. Also used to treat metabolic bone disease associated with malignancy including hypercalcemia of malignancy and bone metastases of solid tumors.

Dosage

2.5 mg orally once daily, or variable dosing intravenously. Should be used in conjunction with adequate supplemental calcium and vitamin D.

Contraindications

Significant renal insufficiency; pregnancy; hypocalcemia.

Adverse Reactions

Dyspepsia, diarrhea, vomiting, gastritis, allergic reaction.

Drug Interactions

Aminoglycosides may lower serum calcium levels with prolonged administration; concomitant use may have additive effect. Increased risk of hypocalcemia with concomitant use of loop diuretics. Risk of renal dysfunction may be increased with concurrent use of thalidomide in patients...

This is a preview of subscription content, log in to check access.

References

  1. Adami S, et al (2002) Three-monthly 2mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Abstract presented at an oral presentation at the World Congress on Osteoporosis, May, Lisbon, Portugal, 036Google Scholar
  2. Delmas P et al (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study: Abstract presented at an oral presentation at the World Congress on Osteoporosis, May, Lisbon, Portugal, 037Google Scholar

Copyright information

© Springer-Verlag 2004